/
INO
$1.12+$0.02 (+1.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$90.5M
82M shares
52-week range
$1.03 – $2.98
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.93%
Moderate
Price (6 mo)
Loading chart…
Change$-112.40
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
www.inovio.com- Employees
- 112
- IPO / List date
- Dec 8, 1998
- HQ
- PLYMOUTH MEETING, PA
Held by traders on TradeandTell
No one on the platform currently holds INO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 643,777 | $1.1M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-01-25 | 1-for-12reverse |
| 2014-06-06 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded INO yet.
